Soligenix, Inc. financial data

Symbol
SNGX on Nasdaq
Industry
Pharmaceutical Preparations
Location
29 Emmons Drive, Suite B 10, Princeton, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
DOR BIOPHARMA INC (to 9/29/2009), ENDOREX CORP (to 10/24/2001), IMMUNOTHERAPEUTICS INC (to 4/30/1996)
Latest financial report
10-K - Q4 2024 - Mar 21, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 160 % +2.92%
Debt-to-equity 162 % -59.9%
Return On Equity -231 % +13.7%
Return On Assets -88.5 % -65.8%
Operating Margin -1.57K % -50.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.16M shares -70%
Common Stock, Shares, Outstanding 2.51M shares +288%
Entity Public Float 3.98M USD -41.9%
Common Stock, Value, Issued 2.51K USD +287%
Weighted Average Number of Shares Outstanding, Basic 1.66M shares +242%
Weighted Average Number of Shares Outstanding, Diluted 1.66M shares +242%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 495K USD -50.4%
Cost of Revenue 451K USD -33.2%
Research and Development Expense 5.22M USD +57.7%
General and Administrative Expense 4.22M USD -5.95%
Operating Income (Loss) -9.44M USD -22.6%
Nonoperating Income (Expense) 764K USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -8.68M USD -9.7%
Income Tax Expense (Benefit) -1.16M USD
Net Income (Loss) Attributable to Parent -8.27M USD -34.6%
Earnings Per Share, Basic -4.98 USD/shares +60.7%
Earnings Per Share, Diluted -4.98 USD/shares +60.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 8.83M USD -7.14%
Property, Plant and Equipment, Net 6.11K USD -48.7%
Operating Lease, Right-of-Use Asset 109K USD -52.6%
Assets 8.97M USD -8.48%
Accounts Payable, Current 668K USD -39.9%
Employee-related Liabilities, Current 336K USD +34%
Accrued Liabilities, Current 2.36M USD -2.43%
Liabilities, Current 4.85M USD -21.2%
Operating Lease, Liability, Noncurrent 11.5K USD -92%
Liabilities 4.85M USD -33.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 45.8K USD +106%
Retained Earnings (Accumulated Deficit) -234M USD -3.66%
Stockholders' Equity Attributable to Parent 4.12M USD +63.3%
Liabilities and Equity 8.97M USD -8.48%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.34M USD +38%
Net Cash Provided by (Used in) Financing Activities -8.99K USD +99%
Common Stock, Shares Authorized 75M shares 0%
Common Stock, Shares, Issued 2.51M shares +288%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.35M USD +56.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 7.82M USD -7.42%
Interest Paid, Excluding Capitalized Interest, Operating Activities 64K USD -70%
Deferred Tax Assets, Valuation Allowance 42.1M USD +4.18%
Deferred Tax Assets, Gross 42.1M USD +4.17%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -8.24M USD -34.2%
Lessee, Operating Lease, Liability, to be Paid 112K USD -52.1%
Operating Lease, Liability, Current 112K USD -8.13%
Lessee, Operating Lease, Liability, to be Paid, Year Two 116K USD -15.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 116K USD -15.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.39K USD -77.5%
Deferred Tax Assets, Operating Loss Carryforwards 28.4M USD +3.33%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 350K shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 26.3K USD -15.1%
Additional Paid in Capital 238M USD +4.31%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 62K USD -4.62%